BMS566419, with the CAS number 1076235-04-5, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of its potential therapeutic applications. It is classified as a selective inhibitor of certain protein kinases, which play crucial roles in various cellular processes, including cell growth, differentiation, and metabolism. The compound's mechanism of action involves the modulation of signaling pathways that are often implicated in cancer and other diseases. BMS566419 is typically characterized by its specific binding affinity to target proteins, which can lead to the inhibition of tumor cell proliferation. In terms of physical properties, detailed information such as solubility, melting point, and stability may vary based on formulation and conditions. As with many investigational compounds, safety and efficacy profiles are evaluated through preclinical and clinical studies to determine its potential as a therapeutic agent. Overall, BMS566419 represents a significant area of interest in drug development, particularly in oncology.

BMS566419

CBS9106 (SL-801) is a CRM1 inhibitor with CRM1-degrading and anti-tumor activity that inhibits CRM1-dependent nuclear export.

CBS9106

Felezonexor is a tyrosine kinase inhibitor that binds to the active site of the enzyme, blocking phosphorylation and inhibiting protein kinase activity. Felezonexor has been shown to inhibit phosphatases and tyrosine phosphatases in solid tumours. These enzymes are involved in cancer cell proliferation and differentiation. Phosphatases also play an important role in antiviral signalling pathways. Felezonexor has been used in treatment of HIV-1 infection and is currently being investigated for use in cancer therapy.

CAS 1076235-04-5: BMS566419

CBS9106

Ref: TM-T14885

Felezonexor

Ref: 3D-BTB23504

CBS9106

Ref: 54-BUP01320